BP-TARGET: Blood Pressure Target in Acute Stroke to Reduce hemorrhaGe After Endovascular Therapy

Sponsor
Fondation Ophtalmologique Adolphe de Rothschild (Other)
Overall Status
Completed
CT.gov ID
NCT03160677
Collaborator
(none)
320
7
2
31.3
45.7
1.5

Study Details

Study Description

Brief Summary

A randomized, multicenter study comparing two strategies: 1 / standard management of systolic blood pressure according to international recommendations (systolic blood pressure <185 mm Hg) versus 2 / intensive blood pressure management Systolic with a target <130 mm Hg.

Condition or Disease Intervention/Treatment Phase
  • Other: Systolic blood pressure target < 130 mm Hg
  • Other: Systolic blood pressure target < 185 mm Hg
N/A

Detailed Description

Patients will be followed for 3 months:
  • inclusion after reperfusion: clinical evaluation with NIHSS (National Institute of Health Stroke Score) score, measurement of blood pressure.

  • within 24 hours after reperfusion: blood pressure measurements

  • at 24 hours: measurement of blood pressure (T0 + 24 h and evaluation of the NIHSS score.

  • Between 24 and 36 hours :cerebral scan (assessment of hemorrhagic transformations and cerebral infarction volumes). For some centers: Cerebral MRI without injection between H24 and H36

  • 72 hours after reperfusion: Cerebral scanner in case of hyperdensity on the initial scanner

  • 3 months after reperfusion: disability assessment by Rankin score

Study Design

Study Type:
Interventional
Actual Enrollment :
320 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Comparison of Two Strategies for Blood Pressure Control in the Setting of Acute Ischemic Stroke to Reduce Cerebral Hemorrhage After Thrombectomy: Systolic Blood Pressure Target of Less Than 130 mmHg vs Less Than 185 mmHg, for 24 Hours Following Reperfusion, in Patients With Cerebral Infarction Due to Occlusion of the Anterior Circulation
Actual Study Start Date :
Jun 21, 2017
Actual Primary Completion Date :
Dec 31, 2019
Actual Study Completion Date :
Jan 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intensive blood pressure management

Other: Systolic blood pressure target < 130 mm Hg
Adaptation of antihypertensive treatments to reach the Systolic blood pressure target < 130 mm Hg

Active Comparator: Standard blood pressure management

Other: Systolic blood pressure target < 185 mm Hg
Adaptation of antihypertensive treatments to reach the Systolic blood pressure target < 185 mm Hg

Outcome Measures

Primary Outcome Measures

  1. Rate of patients with intracranial hemorrhagic complications [Scan performed between 24 and 36 hours after thrombectomy]

    Rate of patients with intracranial hemorrhagic complications (Symptomatic or asymptomatic) on cerebral scan, evaluated with a double centralized blind reading

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Intracranial Occlusion of internal carotid arteries and/or proximal middle cerebral (segment M1) diagnosis made on initial Imaging.

  • Reperfusion after a thrombectomy procedure (defined by a 2b-3 TICI score -Thrombolysis In Cerebral Infarction- score).

Exclusion Criteria:
  • Per-procedure hemorrhagic complications (prior to reperfusion)

  • Systolic blood pressure at baseline <130 mm Hg within one hour of recanalization

  • Pre-existing stroke handicap defined by a Rankin score (modified scale, mRS)> 3

  • Hemodynamically significant carotid stenosis

  • Occlusion of the isolated cervical carotid artery

  • Known pregnancy

  • Legal protection

  • Non-affiliation to a social security scheme

  • Refusal of the patient (or of his / her relatives in case of urgent inclusion)

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU de Bordeaux Bordeaux France
2 Hôpital neurologique Pierre Wertheimer, Hospices Civils de Lyon Lyon France
3 Centre Hospitalier Régional Universitaire Nancy France
4 Hopital Lariboisière Paris France 75010
5 Fondation Ophtalmologique A de Rothschild Paris France 75019
6 Hopital Foch Suresnes France
7 Hopital de purpan Toulouse France 31 100

Sponsors and Collaborators

  • Fondation Ophtalmologique Adolphe de Rothschild

Investigators

  • Principal Investigator: Mikael MAZIGHI, MD PhD, Fondation Ophtalmologique A. de Rothschild

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Fondation Ophtalmologique Adolphe de Rothschild
ClinicalTrials.gov Identifier:
NCT03160677
Other Study ID Numbers:
  • MMI_2016_26
First Posted:
May 19, 2017
Last Update Posted:
Aug 3, 2021
Last Verified:
Aug 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Fondation Ophtalmologique Adolphe de Rothschild
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 3, 2021